---
schema_version: "secwatch.filing_event.v1"
accession: "0001743881-26-000018"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:54:16.121363+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q1 rev $194.5M, Attruby sales $180.6M; $500M share buyback authorized

## Summary
- Q1 2026 total revenues net $194.5M, up from $116.6M YoY; Attruby U.S. net product revenue $180.6M.
- Net loss attributable to common stockholders $164.0M ($0.84 per share), vs $167.4M ($0.88) in Q1 2025.
- Cash, equivalents & marketable securities $940.2M as of March 31, 2026, up from $587.5M at Dec 31.
- Board authorized $500M stock repurchase program; buybacks may occur open market or privately.
- Submitted NDA for BBP-418 (LGMD2I/R9) to FDA; encaleret NDA planned 1H 2026; infigratinib NDA Q3 2026.

## SEC filing metadata
- accession: 0001743881-26-000018
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/0001743881-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/bbio-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001743881-26-000018
- JSON: https://secwatch.observer/filing/0001743881-26-000018.json
- Plain text: https://secwatch.observer/filing/0001743881-26-000018.txt

## Source-grounded claims
- claim_id: 54d610f89d74d5141e3fd8b00bbdb5098db40006
  claim: BridgeBio Pharma, Inc. reported the first quarter ended March 31, 2026 results: revenue $194.5 million.
  evidence_excerpt: except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates - $194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/0001743881-26-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.